NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models
Michael Rugaard Jensen(Novartis (Switzerland)), Patrick Chêne(Novartis (Switzerland))
Cited by 224
Related Papers
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity
|Molecular Cancer Therapeutics|2008|1.1k
Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue
|BMC Chemical Biology|2009|81
Effect of the acylation of TEAD4 on its interaction with co‐activators YAP and TAZ
|Protein Science|2017|69
18F-Radiolabeling and Preliminary Evaluation of a HSP90 ligand
|European Journal of Pharmaceutical Sciences|2020|4